Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO according to BRCA mutation status: Breast cancer mortality: BRCA2 only
It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes breast cancer mortality: BRCA2 only compared with no RRSO according to BRCA mutation status (very low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO according to BRCA mutation status Breast cancer mortality: BRCA2 only It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes breast cancer mortality: BRCA2 only compared with no RRSO according to BRCA mutation status (very low certainty). Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane Headline outcomes only | HR 0.88 [0.42, 1.87] | 3 studies · 5882 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.